MARKET

ADXS

ADXS

Advaxis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5231
-0.0100
-1.88%
After Hours: 0.5100 -0.0131 -2.50% 18:23 08/14 EDT
OPEN
0.5400
PREV CLOSE
0.5331
HIGH
0.5540
LOW
0.5200
VOLUME
773.56K
TURNOVER
--
52 WEEK HIGH
1.480
52 WEEK LOW
0.2051
MARKET CAP
32.23M
P/E (TTM)
-0.3471
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADXS stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

ADXS News

More
Edited Transcript of ADXS earnings conference call or presentation 11-Jun-20 3:00pm GMT
Thomson Reuters StreetEvents · 08/03 20:54
Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
GlobeNewswire · 08/03 13:00
Advaxis inks $20M stock purchase agreement with Lincoln Park Capital
Seeking Alpha - Article · 08/03 12:36
Advaxis Announces Common Stock Purchase Agreement For Up To $20M With Lincoln Park Capital, Which Bought $2M Shares At $0.57/Share
Benzinga · 08/03 12:07
Advaxis to be Featured in Grand Rounds: a Webinar in Biotech and Specialty Pharma, Hosted by Alliance Global Partners
GlobeNewswire · 06/23 13:00
We're A Little Worried About Advaxis's (NASDAQ:ADXS) Cash Burn Rate
Simply Wall St. · 06/17 11:25
Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 06/11 21:14
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update
GlobeNewswire · 06/11 13:00

Industry

Biotechnology & Medical Research
-0.54%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Symbol
Price
%Change

About ADXS

Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
More

Webull offers kinds of Advaxis, Inc. stock information, including NASDAQ:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.